Adjuvant Nivolumab: A New Standard of Care in High-risk MIUC? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
CCR Score Can Guide Treatment After Radiation in Prostate Cancer medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib, With a Median PFS of Nearly Two Years Versus Nine Months for Sunitinib
LENVIMA Plus. | February 16, 2021
KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Published 14 February 2021
(UroToday.com) The 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium included a Best of Journals: Renal Cell Carcinoma Session with Dr. Saby George from the Roswell Park Cancer Institute presenting impactful papers from the medical oncology perspective.
The first paper discussed by Dr. George was Motzer et al. s “Nivolumab Versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Updated Results with Long-Term Follow-Up of the Randomized, Open-Label, Phase 3 CheckMate 025 Trial” was published in
Cancer.
1 CheckMate 025 previously showed superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma along with improved safety and tolerability.